The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.
about
Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.The paired basic amino acid-cleaving enzyme 4 (PACE4) is involved in the maturation of insulin receptor isoform B: an opportunity to reduce the specific insulin receptor-dependent effects of insulin-like growth factor 2 (IGF2).Cationic Cell-Penetrating Peptides Are Potent Furin Inhibitors.Peptides and Peptide Analogs to Inhibit Protein-Protein Interactions.Proprotein convertase inhibition: Paralyzing the cell's master switches.Ghrelin O-acyltransferase (GOAT) is expressed in prostate cancer tissues and cell lines and expression is differentially regulated in vitro by ghrelin.The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.Therapeutic uses of furin and its inhibitors: a patent review.Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors.Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.Elongated and Shortened Peptidomimetic Inhibitors of the Proprotein Convertase Furin.Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3.Evaluation of PACE4 isoforms as biomarkers in thyroid cancer
P2860
Q34092195-10FD5640-A848-4526-8876-8CCA22558EC5Q35048904-8A957D42-927D-4C6E-B063-F2E9670F461CQ35673837-AD625EF8-2144-4BEA-91F5-711513E4608AQ36033291-E30B0D26-1B38-4500-95E2-30C1998EDED8Q36358957-8C416C5E-C8B1-49E5-B486-3E79D709505BQ37048257-7F81BD99-0F88-47AF-98DC-C95B327A3556Q37718282-3764DD56-68A4-4B0B-9B1B-3DECBF7458EDQ38309128-8C3EC76C-F610-40B1-B085-AAD0FDDC5970Q38804945-79704F92-97C5-4120-BB44-4BE8F656056EQ38859830-32B2D80A-D4EE-4B72-BA71-CF290D93E8F4Q38909525-7AC114EE-7F2D-4D2C-B6D2-BEDB38DD1A41Q38956599-196AE51A-BF22-4C88-A922-506A69106B45Q40277816-2F12FC7D-FFFA-49F9-A669-6B557EB2CEB6Q48102100-AE627921-F03D-4506-8C03-D756A63D4E38Q57810683-7999C805-F7C3-4C89-A8F5-AEACD2326F75
P2860
The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The Multi-Leu peptide inhibito ...... ects on prostate cancer cells.
@en
The Multi-Leu peptide inhibito ...... ects on prostate cancer cells.
@nl
type
label
The Multi-Leu peptide inhibito ...... ects on prostate cancer cells.
@en
The Multi-Leu peptide inhibito ...... ects on prostate cancer cells.
@nl
prefLabel
The Multi-Leu peptide inhibito ...... ects on prostate cancer cells.
@en
The Multi-Leu peptide inhibito ...... ects on prostate cancer cells.
@nl
P2093
P2860
P356
P1476
The Multi-Leu peptide inhibito ...... ects on prostate cancer cells.
@en
P2093
Adam Prahl
Anna Kwiatkowska
Christine Levesque
François D'Anjou
Frédéric Couture
Jon R Appel
Martin Fugère
Philippe Moussette
Richard A Houghten
Robert Day
P2860
P304
10501-10511
P356
10.1021/JM3011178
P407
P577
2012-11-14T00:00:00Z